Aclaris Therapeutics Phase 2 atopic dermatitis trial fails, stock drops
Aclaris Therapeutics reported that its Phase 2 ADMIRATION trial of bosakitug (ATI‑045) in moderate‑to‑severe atopic dermatitis did not meet the primary endpoint of percent change in EASI score at week 24 nor any secondary endpoints. The antibody showed target engagement and was well tolerated, but the company will shift focus to its other pipeline programs, including a Phase 2b lichen planus trial of modzatinib, an IND filing for ATI‑9494 later this quarter, and a Phase 2b bispecific antibody trial for eosinophilic esophagitis in early 2027. CEO Neal Walker affirmed the continued commitment to these core programs.
Why it matters
The trial failure triggered a sharp decline in ACRS shares, reducing market value and increasing downside risk for investors. The company’s pivot to other assets means future cash‑flow and valuation will depend on the success of modzatinib, ATI‑9494 and ATI‑052 trials.
Key facts
- 1The Phase 2 ADMIRATION trial did not meet its primary endpoint of percent change from baseline in EASI scores at Week 24. rttnews.com
- 2The trial also failed to achieve any secondary endpoints. rttnews.com
- 3Bosakitug demonstrated robust target engagement of TSLP and was generally well tolerated. rttnews.com
- 4Aclaris initiated a Phase 2b ALPHA trial of modzatinib (ATI‑2138) in lichen planus, enrolling roughly 100 participants. finance.yahoo.com
- 5The company expects to submit an IND for ATI‑9494 later this quarter. finance.yahoo.com
- 6A Phase 2b trial of the bispecific antibody ATI‑052 in eosinophilic esophagitis is planned for the first quarter of 2027. finance.yahoo.com
Open questions
- Stock drop reported as 13.52%, 14.29%, 6%, and 8.2% in pre‑market or intraday trading.
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.